, Tracking Stock Market Picks
Enter Symbol:
Amarin Corporation Plc (AMRN) [hlAlert]

Mkt Outperform
up 112.18 %

Amarin Corporation Plc (AMRN) rated Mkt Outperform with price target $3.50 by Rodman & Renshaw

Posted on: Thursday,  Nov 6, 2008  10:25 AM ET by Rodman & Renshaw

Rodman & Renshaw rated Mkt Outperform Amarin Corporation Plc (NASDAQ: AMRN) on 11/06/2008, when the stock price was $0.99.
Since then, Amarin Corporation Plc has gained 112.18% as of 09/08/2015's recent price of $2.09.
If you would have followed this Rodman & Renshaw's recommendation on AMRN, you would have gained 112.18% of your investment in 2497 days.

Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical company with a focus on cardiovascular disease. Amarin has a range of clinical and preclinical stage compounds to treat central nervous system (CNS) disorders, including Huntington?s disease, myasthenia gravis and Parkinson?s disease. Its cardiovascular programs and non-core CNS programs include AMR101, EN101, Sublingual Apomorphine and AMR 103. The Company's subsidiaries include Amarin Neuroscience Limited, Amarin Pharmaceuticals Ireland Limited, Amarin Pharma Inc, Amarin Finance Limited and Ester Neurosciences Limited.

Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/6/2008 10:25 AM Buy
0.99 3.50
as of 8/27/2015
1 Week down  -10.30 %
1 Month down  -18.35 %
3 Months up  10.00 %
1 YTD up  6.09 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy